A Phase I, Randomized, Double-Blind, Placebo-Controlled Safety, Tolerability and Immunogenicity Study of Candidate HIV-1 Vaccines ChAdOx1.HTI and MVA.HTI With Recombinant HIV-1 Envelope Protein ConM SOSIP.v7 gp140 Vaccine, Adjuvanted With MPLA Liposomes in ART-Suppressed HIV-1 Positive Individuals

NCT05208125 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

30

Enrollment

OTHER

Sponsor class

Conditions

HIV Infection

Interventions

BIOLOGICAL: ChAdOx1.HTI at week 0, ConM SOSIP.v7 at weeks 4, 12 and 28, and MVA.HTI at week 22 (CSSMS).
OTHER: Normal saline solution

Sponsor

IrsiCaixa

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]